Siasos Gerasimos, Tsigkou Vicky, Oikonomou Evangelos, Zaromitidou Marina, Tsalamandris Sotiris, Mourouzis Konstantinos, Vavuranakis Manolis, Anastasiou Maria, Vlasis Konstantinos, Limperi Maria, Gennimata Vasiliki, Boletis John N, Papavassiliou Athanasios G, Tousoulis Dimitris
Vasilissis Sofias 114, TK 115 28, Hippokration Hospital, Athens, Greece.
Curr Med Chem. 2015;22(22):2619-35. doi: 10.2174/0929867322666150415125828.
Atherosclerosis is the main underlying pathology of cardiovascular disease and is precipitated by various hereditary and non-hereditary risk factors. Inflammation is considered an important step in the progression of atherosclerosis and involves numerous cells, mediators and cellular procedures. Therefore, a biomarker able to determine the vascular inflammatory status is imperative as the combination of inflammatory biomarkers with the classic risk factors might provide further information about atherosclerosis progression and cardiovascular risk. The identification of novel inflammatory molecules and the improvement in analytical methods allows the potential implementation of these tests in every day clinical practice. In the current article, we focus on the role of established and novel biomarkers in atherosclerosis progression and in the determination of cardiovascular risk. We also present recent data concerning the risk stratification of patients according to their inflammatory status and the possible anti-inflammatory treatment strategies.
动脉粥样硬化是心血管疾病的主要潜在病理基础，由多种遗传和非遗传风险因素引发。炎症被认为是动脉粥样硬化进展中的一个重要步骤，涉及众多细胞、介质和细胞过程。因此，一种能够确定血管炎症状态的生物标志物至关重要，因为炎症生物标志物与经典风险因素相结合可能会提供有关动脉粥样硬化进展和心血管风险的更多信息。新型炎症分子的鉴定和分析方法的改进使得这些检测有可能在日常临床实践中得到应用。在本文中，我们重点关注已确立的和新型生物标志物在动脉粥样硬化进展及心血管风险测定中的作用。我们还展示了有关根据患者炎症状态进行风险分层以及可能的抗炎治疗策略的最新数据。
